Oppenheimer reiterates Amgen stock rating on cancer drug data

Oppenheimer has reiterated its stock rating for Amgen following the release of data on the company's cancer drug.

According to Investing.com, Oppenheimer has chosen to maintain its current stance on Amgen's stock. The specific details of the rating and the cancer drug data have not been provided.

It is not clear how other financial analysts or institutions have reacted to the cancer drug data or what their current ratings are for Amgen's stock.

Further information on the implications of Oppenheimer's decision and the potential impact on Amgen's stock has not been reported yet.